An investment fund sets out to free biotech’s ‘trapped capital’

An investment fund sets out to free biotech’s ‘trapped capital’

Alis Biosciences says its goal is to return to investors billions of dollars stuck on the balance sheets of “moribund” biotech companies that have suffered significant setbacks.

An Investment Fund Sets Out To Free Biotech’s ‘trapped Capital’ - Data Intelligence

A British investment fund has launched with plans to extract tens of billions of dollars it believes to be “trapped” on the balance sheets of struggling, publicly traded biotechnology companies.   Called Alis Biosciences, the fund aims to return to shareholders the cash invested in these biotechs, while still supporting the companies’ management and boards, according to a Friday statement announcing its debut. Alis said it is targeting “signific…

Alis Biosciences launches fund to free over USD$30 billion of capital trapped in listed development-stage life sciences and biotech companies - PressReach

Significant market inefficiencies have left over USD$30 billion of capital trapped in c.300 listed biotech companies worldwide that have experienced clinical or regulatory setbacks Fund provides efficient mechanism to help investors recoup and recycle trapped cash, while allowing residual science and IP to be developed Fund to be listed on public markets in due course Led by highly experienced industry and investment executives Annalisa Jenkins …

Alis Biosciences launches fund to free over USD$30 billion of capital trapped in listed development-stage life sciences and biotech companies – Optimum Strategic CommunicationsLink to: Will Trump hit foreign pharma companies with tariffs?Scroll to top

Significant market inefficiencies have left over USD$30 billion of capital trapped in c.300 listed biotech companies worldwide that have experienced clinical or regulatory setbacks Fund provides efficient mechanism to help investors recoup and recycle trapped cash, while allowing residual science and IP to be developed Fund to be listed on public markets in due course […]